IRW-PRESS: Glow Lifetech Corp.: Glow Lifetech announces the start of a clinical study with Artemic Support® using MyCell® technology in patients with Long COVID
Acute post-COVID syndrome (PACS), or prolonged COVID, presents as a variety of persistent symptoms in patients four or more weeks after the initial infection with SARS-COV-2. https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html
It is estimated that about 10 to 35% of all COVID patients are affected by Long Covid https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093949/
With the inflammatory response generally believed to be essential to the persistence of symptoms. Therefore, the ability to reduce inflammation could improve patient outcomes, and this study aims to validate Artemic Support® in such settings.
Artemic Support® is a natural health product made with curcumin, frankincense, and vitamin C that reduces inflammatory responses and has been formulated using the ingredients of MyCell® Technology to increase bioavailability and enable faster and more effective cellular uptake of natural agents. This new innovation is the second product in the company’s Artemic line of products to be examined in a clinical trial evaluating safety and efficacy against SARS2-COV-2-related diseases. In April 2020, the company announced that it had submitted its first product, Artemic Rescue, to Health Canada as a natural health product after successfully completing the results of a phase II clinical trial in patients with mild COVID-19. See Glow’s press release dated April 27, 2021
More details about the study
The study is being conducted in collaboration with Swiss PharmaCan, the study’s sponsor, and Glow as co-sponsor along with MGC Pharmaceuticals. A total of 150 patients with acute COVID syndrome (PACS) will participate in the open, single-arm, minimally-interventional study being conducted by UniversalDoctor in 3 primary care centers in Catalonia (Spain). Patients will be given Artemic Support® under the supervision of their physician for 6 weeks, with patients monitored for adverse events throughout the period. Your progress will be measured to see if your symptoms can be reduced.
The Ethics Committee received a positive evaluation and the study has already commenced after enrolling 50 patients. The study is expected to be completed by February 2022, subject to the planned number of participants being reached; Results will be published in the second quarter of 2022. The study is viewed as a pilot study that will be used to generate preliminary data on the safety and efficacy of Artemic Support®; Depending on the results of the current study, a more comprehensive randomized study is expected.
I am delighted that we were able to accept our first patient on December 13th, with very valuable results regarding the safety and efficacy of Artemic Support®, based on groundbreaking MyCell technology, and the potential benefits for millions of people with Long COVID,” said study organizer Dr. Dieter L. Rossman, Senator, of Swiss PharmaCan.
Scientific validation and research are critical to the ongoing commercial efforts of MyCell® technology. Clark Kent, CEO of Glow LifeTech, said Glow is excited to be involved in important work in support of Long COVID symptoms and to recognize the potential health benefits of its cutting-edge ingredients with our partners.
MyCell® Technology is Glow’s proprietary delivery system of natural origin, which dramatically improves the absorption, bioavailability and efficacy of natural active ingredients such as hemp, vitamins, botanicals and more. It transforms poorly absorbed natural active ingredient complexes into water-compatible concentrates that have fast onset of effect, high absorption and accurate dosing. The versatility of MyCell® Concentrates allows them to be used in a variety of product formats such as droppers, beverages, foods, topicals and capsules.
latest news
Prior to Kuzem, the company announced the expansion of its licensed processing facility in Canada and began operating its reactor production facilities. The full message can be found here: https://bit.ly/3e88AJF
Registration: For more information about Glow or to register on the company’s mailing list, please visit: https://www.glowlifetech.com/news
About Glow LifeTech Corp.
Glow LifeTech is a Canada-based biotechnology company focused on creating nutrient- and hemp-based products with greatly improved bioavailability, absorption, and efficacy. Glow holds the rights to groundbreaking, plant-based MyCell Technology®, which transforms poorly absorbed natural compounds into improved water-tolerant concentrates that unlock the full healing potential of valuable compounds.
Internet: www.glowlifetech.com
contact person
James Van Stavren
Glow LifeTech Corp.
Office: 9982-872-647 ext.2
Toll Free: 1-844-247-6633 Ext 2
Bernard Langer
Investor Relations in the European Union
+49 (0) 177774 2314
Call: 855-442-GLOW (4569)
Email: [email protected]
65 International Blvd. Suite 206
Toronto, Ontario M9W 6L9
About Swiss PharmaCan
Micelle Technology AG, the parent company of Swiss PharmaCan, is a dynamic organization dedicated to the research and development of natural active ingredients (such as vitamins and minerals) to improve human health. As one of the innovation leaders in plant-based micelles, Micelle Technology AG offers a unique technology that enables the company to exploit the full potential of its botanical active ingredients.
Internet: www.swisspharmacan.ch
About Universal Doctor
UniversalDoctor: The global digital health company is a social enterprise that develops technology solutions to improve health outcomes around the world. UniversalDoctor has developed nearly 30 technology solutions with international organizations and partners in more than twenty countries, ranging from clinical decision-making tools, mobile data collection systems, data collection tools for clinical trials, clinical and remote monitoring platforms, to smart chatbots. The most recent tools introduced are called UhDa Tools, which is an acronym for: UniversalHealth Digital Access Tools.
Internet: https://www.universaldoctor.com/
About MGC Pharmaceuticals Ltd.
MGC Pharma is a biopharmaceutical company with a nature-to-medicine strategy at the forefront of emerging markets for botanical and herbal medicine. The company’s mission is to build an innovative global biopharmaceutical company that provides standardized and affordable herbal medicines with the highest regulatory compliance to global target markets.
Internet: www.mgcpharma.com.au
Cautionary note regarding forward-looking information
Except for statements of historical facts, this press release contains certain forward-looking information within the meaning of applicable securities laws. Forward-looking information is often identified by terms such as plan, “expect,” “expect,” “intent,” “believe,” “expect,” “estimate,” and other similar words or statements that may or will occur. Forward-looking statements are based on the opinions and estimates at the time the statements were made and are subject to a number of risks, uncertainties and other factors that could cause actual events or results to differ materially from those in the forward-looking information. This also includes delays or uncertainties in official approvals, such as those caused by CSEs. Forward-looking information usually contains uncertainties, including factors that the Company has no control over. There is no guarantee that the technology commercialization plans described in this press release will actually take effect on the terms and within the timeframe set forth herein. The Company undertakes no obligation to update any forward-looking information if circumstances or management’s estimates or opinions change, unless required by applicable law. Readers are cautioned against excessive reliance on forward-looking statements. For more information about the risks and uncertainties that may affect the financial results, see the Company’s filings with the Canadian Securities Commissions which are posted at www.sedar.com.
The source language (usually English) in which the original text is published is the official, authorized and legally valid version. This translation is included for better understanding. The German version can be abbreviated or abbreviated. We assume no responsibility or liability for the content, correctness, suitability or accuracy of this translation. From the translator’s point of view, the message does not constitute a buy or sell recommendation! Please note the original report in English at www.sedar.com, www.sec.gov, www.asx.com.au/ or on the company’s website!
You can find the original English report under the following link:
https://www.irw-press.at/press_html.aspx?messageID=63361
The translated message can be found under the following link:
https://www.irw-press.at/press_html.aspx?messageID=63361&tr=1
Register for the newsletter:
The current press releases of this company directly in your mailbox:
http://www.irw-press.com/alert_subscription.php?lang=de&isin=CA37989H1091
Announcement submitted by IRW-Press.com. The broadcaster is responsible for the content.
Free reprint is permitted provided the source is acknowledged.
Source: dpa-AFX
“Certified tv guru. Reader. Professional writer. Avid introvert. Extreme pop culture buff.”
More Stories
Classic espionage, cyber attacks, creating economic dependencies, and technology withdrawal –
How the technology behind ChatGPT powers this bot
Mercedes G580 with EQ technology: The G-Class has become electric